Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells

BACKGROUND: Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to side-effects including hyperglycemia. The AMPK inhibitor and anti-diabetic drug metformin may counteract everolimus-induced hyperglycemia, as well as enhancing anti-cancer efficacy. We i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ariaans, Gerke, Jalving, Mathilde, Vries, Emma Geertruida Elisabeth de, Jong, Steven de
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372253/
https://www.ncbi.nlm.nih.gov/pubmed/28356082
http://dx.doi.org/10.1186/s12885-017-3230-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372253/
https://www.ncbi.nlm.nih.gov/pubmed/28356082
http://dx.doi.org/10.1186/s12885-017-3230-8

Ejemplares similares